Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled around 1,100 people in total across three groups. Approximately 370 people received a lower dose of the study drug farletuzumab (1.25 mg/kg) combined with standard chemotherapy (taxane and carboplatin), around 366 received a higher dose of farletuzumab (2.5 mg/kg) with the same chemotherapy, and roughly 364 received a dummy (placebo) treatment alongside the same chemotherapy. The trial's main goal was to measure how long it took for participants' cancer to grow or spread again — known as "progression-free survival" — and several secondary measures were also tracked, including how long participants lived overall. The reported data shows that for the primary measure — the time until the cancer progressed or death occurred — the lower-dose farletuzumab group recorded a median (the midpoint value for the group) of 9.5 months, the higher-dose group recorded 9.7 months, and the placebo group recorded 9.0 months. For overall survival (time from the start of the trial until death from any cause), the reported figures were 28.7 months, 32.1 months, and 29.1 months for the lower-dose, higher-dose, and placebo groups respectively. A blood marker for cancer called CA-125 was also used to track progression, and the reported times were 13.2, 18.1, and 12.0 months across the same three groups. When looking at the proportion of participants whose tumours shrank by a meaningful amount, the reported figures were approximately 57.6%, 58.2%, and 55.8% for the lower-dose, higher-dose, and placebo groups respectively. The proportion of participants whose second period of remission lasted longer than their first was reported as 4.0%, 6.5%, and 4.5% across the three groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with a specific type of ovarian cancer (non-mucinous epithelial ovarian cancer), or a related cancer starting in the peritoneum or fallopian tubes, confirmed by a lab test
- Your cancer can be measured on a CT or MRI scan
- Your cancer has come back between 6 and 24 months after finishing your first course of platinum-based chemotherapy
- You have previously had surgery to remove as much of the tumour as possible, followed by chemotherapy using platinum and taxane drugs
- You may have previously received bevacizumab as a maintenance treatment, as long as your last dose was at least 30 days before the study starts (no other maintenance chemotherapy or cancer vaccine treatments are allowed)
- You are considered suitable to receive carboplatin and taxane chemotherapy again
- You have little or no nerve damage (such as numbness or weakness) from previous treatment (confirm with trial site)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Your cancer did not respond to your first platinum-based chemotherapy, or it came back either less than 6 months or more than 24 months after finishing it
- You have already received any treatment for your cancer since it came back
- The cancer has spread to your brain or central nervous system
- You have had another active serious cancer that required treatment within the last 5 years
- You have had a known allergic reaction to a monoclonal antibody treatment before, or have developed certain antibodies against such treatments (confirm with trial site)
- You have previously been treated with a drug called MORAb-003 (farletuzumab)
- There is a medical reason why you cannot safely receive taxane chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 6 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-free Survival (PFS)
Other options
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.